Home page News Related Researches 2000-2009

Action of melatonin on bone marrow depression induced by cyclophosphamide in acute toxicity phase

Published on Monday, 22 March 2021

Abstract

Background: In the course of the last few years, various studies have researched the relations linking melatonin (MLT) with hematopoiesis and the immune-hematopoietic system. Nevertheless, to date there are numerous issues still opened and many questions are yet unanswered. Much emphasis has been recently placed on the reducing role of MLT, which has been demonstrated by many studies to mitigate the genotoxic damage inflicted by various alkylating agents. Although in vitro MLT has shown to be effective in limiting the cytological alterations provoked by chemotherapeutic drugs, some clinical studies seem to point to a somewhat lower effectiveness in countering chemotherapy-induced leukopenia and anemia.

Objective: The aim of this study was to evaluate the activity exerted by pharmacological doses of MLT in limiting leukopenia, anemia and other hemocytometric modifications in animals facing acute toxicity caused by the treatment with cyclophosphamide (CP). Moreover, we have compared the activity of MLT with well-known alpha-tocopherol/ascorbic acid antioxidant system.

Results: Our results indicate that overall MLT exerts a remarkable countering activity towards leukopenia and anemia in the early phase of administration of CP.

Conclusions: Our findings suggest possible active involvement of MLT in hematopoiesis and erythrocyte- and leukocyte turnover. This paper summarizes the essential aspects of the available literature, researching the possible relations between MLT and immune-hematopoietic system.

NOTE: This publication mentions:

Ref. N. 23: Di Bella L, Rossi MT, Pellegrino N et al. (1969). Ruolo del sistema abenulo-epifisario nella regolazione del tasso piastrinemico. Boll Soc Ital Biol Sper. Vol. XLV, N. 20 bis;
Ref. N. 24: Di Bella L, Rossi MT, Scalera G (1979, a). Perspectives in pineal functions. Prog Brain Res. 52: 475–8;
Ref. N. 25: Di Bella L, Rossi MT, Gualano L, Scalera G (1979, b). Effect of the simultaneous action of melatonin and ADP in megakaryocytes in vitro. Boll Soc Ital Biol Sper. 55(5): 389–93;
Ref. N. 26: Di Bella L, Gualano L, Rossi MT, Scalera G (1979, c). The action of melatonin (MLT) on platelet metabolism in vitro. Boll Soc Ital Biol Sper. 55(4): 323–6;
Ref. N. 27: Di Bella L, Scalera G, Rossi MT, Gualano L (1979, d). L’Aggregazione Piastrinica in presenza di melatonina. Bollettino società italiana di fisiologia. Riunione primaverile dell’anno sociale 1978/79;
Ref. N. 28: Di Bella L, Rossi MT (1980). Red Blood cells generation and melatonin. International Symposium on melatonin. Bremen, 28–30 September 1980;
Ref. N. 29: Di Bella L, Bruschi C, Gualano L (2002). Melatonin effects on megakaryocyte membrane patch-clamp outward K+ current. Med Sci Monit. 8(12): BR527–31;
Ref. N. 30: Di Bella L, Gualano L (2006). Key aspects of melatonin physiology: thirty years of research. Neuro Endocrinol Lett. 27(4): 425–32;
Ref. N. 102: Rossi MT, Ferrari R, Biral P, Di Bella L, Zini I (1974). Tasso leucocitario e trombopenia. Boll Soc Ital Biol Sper. Vol. L, N. 20 bis;
Ref. N. 103: Rossi MT, Scalera G, Di Bella L (1976). Azione mielotropa della melatonina. Boll Soc Ital Biol Sper. Vol. LII, N. 18 bis;
Ref. N. 104: Rossi MT, Di Bella L (1988). Melatonin in thrombocytogenesis. The pineal gland and cancer, edited by Gupta et al. : BrainResearch Promotion. 183–94.

Download the complete article

About this publication.

- The Di Bella Method (A Fixed Part - Melatonin tablets. From 30-40mg/day up to 200mg/day orally in patients with advanced stage of cancer disease and/or patients without respond to traditional treatments);

- Melatonin use in cancer patients have started in 1974, when melatonin prepared according to Prof. Di Bella’s formulation [...]. For 11 days was administered to the patient, admitted to the general medical ward at the Maggiore-Pizzardi Hospital in Bologna, very slowly (over approx. 8 hours) and intravenously administered 1000 mg of melatonin for 11 days. During the course of each day, the patient was intravenously administered 4 saline drips of 500 ml, each containing ten 25 mg bottles of freeze-dried melatonin, lasting 2 hours, totaling 1000 mg per day. No other drug of any kind was administered in order to ascertain the effect of the MLT without interference [...]. From Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings;

- About Melatonin - In vitro, review and in vivo publications;

- Publication: Melatonin anticancer effects: Review (from Di Bella's Foundation);

- Publication: Key aspects of melatonin physiology: 30 years of research (from Di Bella's Foundation);

- The Di Bella Method (A Fixed Part - Alpha tocopheryl acetate/Vitamin E, approximately 20 grams per day orally);

- Cancer and Vitamin E (analogues and/or derivatives) and cancer - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - All-Trans Retinoic Acid, Analogues and/or Derivatives - Approximately 60mg per day orally: 40mg per day Beta-Carotene/β-Carotene, 10mg per day ATRA and 10mg per day Axerophthol palmitate);

- All-Trans-Retinoic Acid (ATRA - analogues and/or derivatives) - In vitro, review and in vivo publications;

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- The Di Bella Method (A Fixed Part - Vitamin C/Ascorbic Acid, 2–4 grams, twice a day orally);

- The Di Bella Method (A Fixed Part - Cyclophosphamide 50mg tablets and/or Hydroxyurea 500mg tablets, one or two per day);

- The Di Bella Method (A Variable Part - Omega 3 Essential/Unsaturated Fatty Acids. From 1.5 grams up to 3.0 grams per day orally);

- The Di Bella Method (A Fixed Part - Somatostatin, Octreotide, Sandostatin LAR, analogues and/or derivatives);